Ruland Sean, Gorelick Philip B
Center for Stroke Research and Section of Cerebrovascular Disease and Neurological Critical Care, Department of Neurological Sciences, Rush Medical College, 1645 West Jackson, Suite 400, Chicago, IL 60612, USA.
Curr Atheroscler Rep. 2003 Jan;5(1):38-43. doi: 10.1007/s11883-003-0067-1.
Statins and angiotensin-converting enzyme (ACE) inhibitors are an important component of our armamentarium for stroke prevention. Both of these classes of agents have a primary mechanism of action of reducing the level of the respective risk factor. They also have mechanisms of action that may confer benefits beyond what is believed to be the primary action of the agent. This has led to speculation that statins reduce stroke risk by means beyond cholesterol lowering, and ACE inhibitors reduce stroke risk by means beyond blood pressure lowering. We review the mounting evidence that suggests that statins and ACE inhibitors have so-called pleiotropic effects that may lead to stroke prevention.
